Intellia Therapeutics, Inc. (NTLA) Stock Rating Lowered by Chardan Capital
Intellia Therapeutics, Inc. (NASDAQ:NTLA) was downgraded by research analysts at Chardan Capital from a “buy” rating to a “neutral” rating in a report issued on Tuesday. They currently have a $20.00 price objective on the stock. Chardan Capital’s target price would indicate a potential upside of 0.65% from the stock’s previous close.
Several other analysts have also recently issued reports on the company. Cann restated a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Jefferies Group LLC restated a “buy” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a report on Saturday, July 22nd. Oppenheimer Holdings, Inc. began coverage on Intellia Therapeutics in a report on Tuesday, July 18th. They issued a “market perform” rating for the company. TheStreet upgraded Intellia Therapeutics from a “d+” rating to a “c-” rating in a report on Thursday, July 6th. Finally, Credit Suisse Group set a $24.00 price target on Intellia Therapeutics and gave the company a “buy” rating in a research note on Saturday, June 3rd. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $24.83.
Shares of Intellia Therapeutics (NTLA) opened at 19.87 on Tuesday. The company’s market capitalization is $717.55 million. The firm’s 50-day moving average is $16.56 and its 200 day moving average is $14.58. Intellia Therapeutics has a 12 month low of $10.83 and a 12 month high of $22.28.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. The company had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business’s quarterly revenue was up 40.5% on a year-over-year basis. Equities analysts expect that Intellia Therapeutics will post ($1.74) EPS for the current year.
WARNING: “Intellia Therapeutics, Inc. (NTLA) Stock Rating Lowered by Chardan Capital” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/intellia-therapeutics-inc-ntla-stock-rating-lowered-by-chardan-capital/1533321.html.
In related news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 12.80% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Airain ltd bought a new stake in Intellia Therapeutics during the first quarter worth about $381,000. M&T Bank Corp bought a new stake in Intellia Therapeutics during the first quarter worth about $162,000. Paulson & CO. Inc. bought a new stake in Intellia Therapeutics during the first quarter worth about $1,107,000. UBS Group AG raised its stake in Intellia Therapeutics by 432.0% in the first quarter. UBS Group AG now owns 60,935 shares of the company’s stock worth $859,000 after buying an additional 49,480 shares in the last quarter. Finally, Norges Bank acquired a new position in Intellia Therapeutics during the fourth quarter worth approximately $886,000. 46.52% of the stock is currently owned by institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.